Primary immunodeficiencies in the Netherlands

National patient data demonstrate the increased risk of malignancy

B.M. Jonkman-Berk, J.M. van den Berg, I.J.M. ten Berge, G.J. Driessen, V.A.S.H. Dalm, J.T. van Dissel, M. van Deuren, P.M. Ellerbroek, M. van der Flier, P.M. van Hagen, J.M. van Montfrans, A. Rutgers, E.H. Schölvinck, E. de Vries, R.T. van Beem, T.W. Kuijpers, R.G.M. Bredius

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Purpose To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. Results In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was ‘predominantly antibody disorder (PAD)’ (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular ‘lymphoma’ and ‘skin cancer’. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a > 10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. Conclusions The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy. Keywords: Primary immunodeficiencies, Infection, Transplantation, Malignancy
Original languageEnglish
Pages (from-to)154–162
JournalClinical Immunology
Volume156
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Netherlands
Lymphoma
Neoplasms
Endocrine System Diseases
Hematologic Diseases
Leukemia
Incidence

Cite this

Jonkman-Berk, B. M., van den Berg, J. M., ten Berge, I. J. M., Driessen, G. J., Dalm, V. A. S. H., van Dissel, J. T., ... Bredius, R. G. M. (2015). Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy. Clinical Immunology, 156(2), 154–162. https://doi.org/10.1016/j.clim.2014.10.003
Jonkman-Berk, B.M. ; van den Berg, J.M. ; ten Berge, I.J.M. ; Driessen, G.J. ; Dalm, V.A.S.H. ; van Dissel, J.T. ; van Deuren, M. ; Ellerbroek, P.M. ; van der Flier, M. ; van Hagen, P.M. ; van Montfrans, J.M. ; Rutgers, A. ; Schölvinck, E.H. ; de Vries, E. ; van Beem, R.T. ; Kuijpers, T.W. ; Bredius, R.G.M. / Primary immunodeficiencies in the Netherlands : National patient data demonstrate the increased risk of malignancy. In: Clinical Immunology. 2015 ; Vol. 156, No. 2. pp. 154–162.
@article{3466f5c24fb8467394a904a9947002e5,
title = "Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy",
abstract = "Purpose To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. Results In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was ‘predominantly antibody disorder (PAD)’ (60.4{\%}). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10{\%} of the PID patients suffered from a malignancy, in particular ‘lymphoma’ and ‘skin cancer’. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a > 10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. Conclusions The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy. Keywords: Primary immunodeficiencies, Infection, Transplantation, Malignancy",
author = "B.M. Jonkman-Berk and {van den Berg}, J.M. and {ten Berge}, I.J.M. and G.J. Driessen and V.A.S.H. Dalm and {van Dissel}, J.T. and {van Deuren}, M. and P.M. Ellerbroek and {van der Flier}, M. and {van Hagen}, P.M. and {van Montfrans}, J.M. and A. Rutgers and E.H. Sch{\"o}lvinck and {de Vries}, E. and {van Beem}, R.T. and T.W. Kuijpers and R.G.M. Bredius",
year = "2015",
doi = "10.1016/j.clim.2014.10.003",
language = "English",
volume = "156",
pages = "154–162",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

Jonkman-Berk, BM, van den Berg, JM, ten Berge, IJM, Driessen, GJ, Dalm, VASH, van Dissel, JT, van Deuren, M, Ellerbroek, PM, van der Flier, M, van Hagen, PM, van Montfrans, JM, Rutgers, A, Schölvinck, EH, de Vries, E, van Beem, RT, Kuijpers, TW & Bredius, RGM 2015, 'Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy', Clinical Immunology, vol. 156, no. 2, pp. 154–162. https://doi.org/10.1016/j.clim.2014.10.003

Primary immunodeficiencies in the Netherlands : National patient data demonstrate the increased risk of malignancy. / Jonkman-Berk, B.M.; van den Berg, J.M.; ten Berge, I.J.M.; Driessen, G.J.; Dalm, V.A.S.H.; van Dissel, J.T.; van Deuren, M.; Ellerbroek, P.M.; van der Flier, M.; van Hagen, P.M.; van Montfrans, J.M.; Rutgers, A.; Schölvinck, E.H.; de Vries, E.; van Beem, R.T.; Kuijpers, T.W.; Bredius, R.G.M.

In: Clinical Immunology, Vol. 156, No. 2, 2015, p. 154–162.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Primary immunodeficiencies in the Netherlands

T2 - National patient data demonstrate the increased risk of malignancy

AU - Jonkman-Berk, B.M.

AU - van den Berg, J.M.

AU - ten Berge, I.J.M.

AU - Driessen, G.J.

AU - Dalm, V.A.S.H.

AU - van Dissel, J.T.

AU - van Deuren, M.

AU - Ellerbroek, P.M.

AU - van der Flier, M.

AU - van Hagen, P.M.

AU - van Montfrans, J.M.

AU - Rutgers, A.

AU - Schölvinck, E.H.

AU - de Vries, E.

AU - van Beem, R.T.

AU - Kuijpers, T.W.

AU - Bredius, R.G.M.

PY - 2015

Y1 - 2015

N2 - Purpose To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. Results In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was ‘predominantly antibody disorder (PAD)’ (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular ‘lymphoma’ and ‘skin cancer’. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a > 10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. Conclusions The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy. Keywords: Primary immunodeficiencies, Infection, Transplantation, Malignancy

AB - Purpose To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. Results In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was ‘predominantly antibody disorder (PAD)’ (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular ‘lymphoma’ and ‘skin cancer’. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a > 10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. Conclusions The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy. Keywords: Primary immunodeficiencies, Infection, Transplantation, Malignancy

U2 - 10.1016/j.clim.2014.10.003

DO - 10.1016/j.clim.2014.10.003

M3 - Article

VL - 156

SP - 154

EP - 162

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -

Jonkman-Berk BM, van den Berg JM, ten Berge IJM, Driessen GJ, Dalm VASH, van Dissel JT et al. Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy. Clinical Immunology. 2015;156(2):154–162. https://doi.org/10.1016/j.clim.2014.10.003